Annovis Advances Buntanetap in Alzheimer’s Phase 3
Malvern, Pennsylvania — August 14, 2026 Annovis Bio, Inc. announced that its pivotal Phase 3 Alzheimer’s disease trial of...
Alzheimer’s Disease
Advertisement
Genedata Advances AI Biomarker Discovery in Alzheimer’s Research
Basel, Switzerland, August 13, 2026 Genedata, a Danaher company providing enterprise software for biopharmaceutical research and development, has launched...
CytoDyn Doses First Patient in Phase 2a Alzheimer’s Trial of Leronlimab
VANCOUVER, Wash., June 11, 2026 CytoDyn Inc. announced that the first patient has been dosed in the Phase 2a...
IGC Pharma Completes Enrollment in Phase 2 CALMA Trial
POTOMAC, Md., June 10, 2026 IGC Pharma, Inc. (NYSE American: IGC) announced that its Phase 2 CALMA clinical trial...
Elixiron Reports Positive Phase 2 Enrupatinib Data in Alzheimer’s Disease
CAMBRIDGE, Mass. and TAIPEI, June 10, 2026 Elixiron Immunotherapeutics announced positive interim results from its ongoing Phase 2 proof-of-concept...
Advertisements
Alpha Cognition Reports Positive BEACON Study Results for ZUNVEYL
VANCOUVER, B.C. & GRAPEVine, Texas, June 9, 2026 Alpha Cognition Inc. announced positive top-line results from the BEACON Phase...
AlzeCure and Eli Lilly Partner on Alzheimer’s Drug ACD680
STOCKHOLM, Sweden, June 9, 2026 AlzeCure Pharma announced a global collaboration and out-licensing agreement with Eli Lilly and Company...
NanoDetection and Oligomerix Partner to Advance Tau-Based Neurodegenerative Diagnostics
FRANKLIN, Ohio & BRONX, N.Y., June 2026 NanoDetection Technology (NDT) and Oligomerix announced an exclusive worldwide licensing agreement granting...
TOBY Gains FDA Breakthrough Status for Alzheimer’s Test
AUSTIN, Texas, May 26, 2026 TOBY, Inc., a biotechnology company focused on non-invasive disease detection technologies, has announced that...
Tempus AI and Bristol Myers Squibb Expand AI Clinical Trial Partnership
CHICAGO, Illinois, May 2026 Tempus AI announced an expanded strategic collaboration with Bristol Myers Squibb aimed at improving the...
Advertisement
